Longevity scientist David Sinclair is preparing to test an oral drug mixture, code-named SL-100, designed for whole-body rejuvenation. These human trials are intended to compete in the XPrize Foundation's Healthspan Competition, which offers a $101 million prize for teams demonstrating a significant reversal of apparent age. The approach uses chemical reprogramming to reset epigenetic marks, aiming for broader effects than previous gene therapy trials. AI
IMPACT This research could lead to new therapeutic approaches for aging, potentially impacting healthcare and life extension industries.
RANK_REASON The cluster describes plans for human trials of a novel drug for age reversal, which constitutes a research milestone. [lever_c_demoted from research: ic=2 ai=0.4]
Read on MIT Technology Review →
- Betterhumans
- Harvard Medical School
- James Clement
- Life Biosciences
- Peter Diamandis
- Soxogen
- XPRIZE Foundation
AI-generated summary · Google Gemini · from 2 sources. How we write summaries →